WuXi Biologics boosts issued shares through option exercises

WuXi Biologics (Cayman) Inc. reported an increase in its issued ordinary shares on November 27, 2025, primarily due to the exercise of share options and awards. The total number of issued shares rose from 4,117,744,981 to 4,128,113,981. This change reflects several transactions, including the issuance of 165,000 new shares at HK$1.74 each and another 145,000 shares at HK$1.48 each. Both were related to share awards and options granted to participants not classified as directors. These issuances represented 0.00401% and 0.00352%, respectively, of the existing issued shares before the relevant events.

The most substantial increase came from the issuance of 10,059,000 ordinary shares at HK$1.29 each. These shares were issued for the exercise of share options under the Pre-IPO Share Option Scheme, adopted by the company on January 5, 2016, as amended. This transaction alone accounted for a 0.24428% increase relative to the company’s previously issued shares. All transactions were confirmed to be duly authorized, compliant with listing rules, and legally sound, with all necessary funds received and documents filed.